Get the Stockscreener App
1.70
0.58%
-0.01
Biorestorative Therapies Inc stock is traded at $1.70, with a volume of 17,939.
It is down -0.58% in the last 24 hours and down -6.08% over the past month.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
See More
Previous Close:
$1.71
Open:
$1.68
24h Volume:
17,939
Relative Volume:
0.05
Market Cap:
$12.83M
Revenue:
$149.50K
Net Income/Loss:
$-6.96M
P/E Ratio:
-1.25
EPS:
-1.36
Net Cash Flow:
$-6.37M
1W Performance:
-0.58%
1M Performance:
-6.08%
6M Performance:
+7.59%
1Y Performance:
+36.00%
1-Day Range:
$1.6609
$1.73
1-Week Range:
$1.64
$1.7778
52-Week Range:
$1.03
$2.55
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
1.70 | 12.83M | 149.50K | -6.96M | -6.37M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 2.3% – Here’s Why - Defense World
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies - The Globe and Mail
EQS-News: Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies - markets.businessinsider.com
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease - FinancialContent
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - TradingView
BioRestorative unaffected by new U.S. tariffs, continues clinical trials - Investing.com South Africa
BioRestorative confirms no material impact from reciprocal tariffs - marketscreener.com
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - Yahoo
FDA Fast-Tracks BioRestorative's Therapy as $10M Cash Shields Growth - Stock Titan
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 3.9% – Time to Buy? - Defense World
BioRestorative Therapies Reports Strong Growth Amid Challenges - MSN
Equities Analysts Issue Forecasts for BRTX FY2029 Earnings - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q4 2024 Earnings Call Transcript - MSN
Earnings call transcript: BioRestorative’s Q4 2024 sees revenue growth, stock dip - Investing.com India
BioRestorative Therapies (BRTX) Projected to Post Earnings on Friday - Defense World
BioRestorative Therapies Reports Financial Gains and Clinical Progress - TipRanks
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update - TradingView
175% Revenue Surge: BioRestorative's Breakthrough Year With FDA Fast Track Success - Stock Titan
Earnings Preview For BioRestorative Therapies - Benzinga
BIORESTORATIVE THERAPIES Earnings Preview: Recent $BRTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
BioRestorative Therapies Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
BioRestorative Therapies (BRTX) Projected to Post Earnings on Thursday - Defense World
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025 - The Manila Times
BioRestorative Therapies, Inc. Scheduled to Release 2024 Financial Results on March 27, 2025 - Nasdaq
Clinical-Stage Stem Cell Leader BioRestorative Therapies Reveals 2024 Financial Results Date - Stock Titan
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Revolutionary: Stem Cell Therapy Puts Creative Medical on Profit Track - GeeksULTD
Revolutionary Breakthrough: BioRestorative Therapies Turns Profit! - GeeksULTD
BioRestorative Therapies (NASDAQ:BRTX) Trading 3.6% Higher – Should You Buy? - Defense World
Will BioRestorative's Cell Therapy Revolutionize The Spine Treatment Forte? - RTTNews
Reviewing Eastgate Biotech (OTCMKTS:ETBI) and BioRestorative Therapies (OTCMKTS:BRTX) - The AM Reporter
BioRestorative Therapies Says FDA Clears BRTX-100 Trial in Chronic Cervical Discogenic Pain - Marketscreener.com
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain - The Manila Times
BioRestorative announces FDA clearance of IND for Phase 2 BRTX-100 trial - TipRanks
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update - Yahoo Finance
What Will BioRestorative Reveal About Its Stem Cell Therapies on February 27? - StockTitan
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline - The Manila Times
FDA Green Light? BioRestorative Teases Major Clinical Breakthrough for Stem Cell Therapies - Stock Titan
Head to Head Review: BioRestorative Therapies (NASDAQ:BRTX) and Quipt Home Medical (NASDAQ:QIPT) - The AM Reporter
Comparing Quipt Home Medical (NASDAQ:QIPT) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program - GlobeNewswire
Can This FDA-Fast-Tracked Therapy Finally Solve Chronic Back Pain? Phase 2 Data Shows Promise - StockTitan
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):